Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer.

Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, Streiff MB, Garcia DA, Liebman HA, Belani CP, O'Reilly EM, Patel JN, Yimer HA, Wildgoose P, Burton P, Vijapurkar U, Kaul S, Eikelboom J, McBane R, Bauer KA, Kuderer NM, Lyman GH; CASSINI Investigators.

N Engl J Med. 2019 Feb 21;380(8):720-728. doi: 10.1056/NEJMoa1814630.

PMID:
30786186
2.

Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.

Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A; ASPIRE Investigators.

N Engl J Med. 2015 Jan 8;372(2):142-52. doi: 10.1056/NEJMoa1411321. Epub 2014 Dec 6.

3.

Long-term safety and efficacy of factor IX gene therapy in hemophilia B.

Nathwani AC, Reiss UM, Tuddenham EG, Rosales C, Chowdary P, McIntosh J, Della Peruta M, Lheriteau E, Patel N, Raj D, Riddell A, Pie J, Rangarajan S, Bevan D, Recht M, Shen YM, Halka KG, Basner-Tschakarjan E, Mingozzi F, High KA, Allay J, Kay MA, Ng CY, Zhou J, Cancio M, Morton CL, Gray JT, Srivastava D, Nienhuis AW, Davidoff AM.

N Engl J Med. 2014 Nov 20;371(21):1994-2004. doi: 10.1056/NEJMoa1407309.

4.

Newly diagnosed congenital factor VII deficiency and utilization of recombinant activated factor VII (NovoSeven(®)).

Bartosh NS, Tomlin T, Cable C, Halka K.

Clin Pharmacol. 2013;5:53-8. doi: 10.2147/CPAA.S39772. Epub 2013 Mar 15.

5.

Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies.

Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V; French Study Group for aHUS/C3G.

Nat Rev Nephrol. 2012 Nov;8(11):643-57. doi: 10.1038/nrneph.2012.214. Epub 2012 Oct 2. Review.

PMID:
23026949
6.

Reduced dose maintenance eculizumab in atypical hemolytic uremic syndrome (aHUS): an update on a previous case report.

Ohanian M, Cable C, Halka K.

Clin Pharmacol. 2011;3:45-50. doi: 10.2147/CPAA.S23687. Epub 2011 Nov 1.

7.

Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome.

Ohanian M, Cable C, Halka K.

Clin Pharmacol. 2011;3:5-12. doi: 10.2147/CPAA.S17904. Epub 2011 May 24.

8.

Potentiation of renal tumorigenicity by cyclosporine A in streptozotocin diabetic rats.

Reddi AS, Jyothirmayi GN, Halka K, Khan MY.

Cancer Lett. 1991 Feb;56(2):109-15.

PMID:
1825617
9.

A rare restriction enzyme site polymorphism in the breakpoint cluster region (bcr) of chromosome 22.

Benn P, Grossman A, Soper L, Halka K, Eisenberg A, Gascon P.

Leukemia. 1988 Nov;2(11):760-2.

PMID:
2903273
10.

Long-term marrow cultures from mice with busulfan-induced chronic latent aplasia.

Halka KG, Caro J, Erslev AJ.

J Lab Clin Med. 1987 Jun;109(6):698-705.

PMID:
3585143
11.

Granulopoiesis in long-term culture by marrow from mice with busulfan-induced chronic latent aplasia.

Boyd RL, Caro J, Halka KG, Erslev AJ.

Int J Cell Cloning. 1986 Sep;4(5):357-67.

PMID:
3772175

Supplemental Content

Loading ...
Support Center